Olanzapine vs NK1 antagonist: Serious adverse events
- Population
- cancer patients
- Intervention
- Olanzapine
- Comparison
- NK1 antagonist
- Outcome
- Serious adverse events
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Olanzapine vs NK1 antagonist Serious adverse events · adults with cancer It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty). Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults (2018) · Cochrane Headline outcomes only | RR 0.33 [0.02, 7.32] | Not reported | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Olanzapine vs placebo/no treatment · cancer patients · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.